Publications

Publications

Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.

J Mol Med (Berl). 2016 Dec;94(12):1411-1422

Wang T, Abou-Ouf H, Hegazy SA, Alshalalfa M, Stoletov K, Lewis J, Donnelly B, Bismar TA

Abstract

Ankyrin G (ANK3) is a member of the Ankyrin family, which functions to provide cellular stability by anchoring the cytoskeleton to the plasma membrane. Deregulation of ANK3 expression has been observed in multiple human cancers but its mechanism remains unknown. ANK3 expression in relation to disease progression and patients’ outcome was investigated in two cohorts of prostate cancer (PCA). Mechanistic studies were carried out in vitro and in vivo using several PCA cell lines and the avian embryo model. Silencing ANK3 resulted in significant reduction of cell proliferation through an AR-independent mechanism. Decreased ANK3 expression delayed S phase to G2/M cell cycle transition and reduced the expression of cyclins A and B. However, cells with knocked-down ANK3 exhibited significant increase in cell invasion through an AR-dependent mechanism. Furthermore, we found that ANK3 is a regulator of AR protein stability. ANK3 knockdown also promoted cancer cell invasion and extravasations in vivo using the avian embryo model (p < 0.01). In human samples, ANK3 expression was dramatically upregulated in high grade intraepithelial neoplasia (HGPIN) and localized PCA (p < 0.0001). However, it was downregulated castration resistant stage (p < 0.0001) and showed inverse relation to Gleason score (p < 0.0001). In addition, increased expression of ANK3 in cancer tissues was correlated with better cancer-specific survival of PCA patients (p = 0.012).

KEY MESSAGE:

Silencing ANK3 results in significant reduction of cell proliferation through an AR-independent mechanism. ANK3 knockdown results in significant increase in cell invasion through an AR-dependent mechanism. ANK3 is a regulator of AR protein stability. ANK3 knockdown also promotes cancer cell invasion and extravasation in vivo using the avian embryo model.

PubMed

Its nearly time for the 2018 APCaRI Fall Symposium!

APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, in Banff, Alberta on October 26 to 27, 2018. Please welcome our two invited speakers who will be joining the Symposium this year:

Alison Allan, PhD
Chair, Department of Anatomy & Cell Biology
Associate Professor, Departments of Anatomy & Cell Biology and Oncology
Western University, Ontario CA
and
Melina Cimler, PhD
CEO and Founder
PandiaDx LLC
Frisco, Texas

Previous fall symposia have had over 60 participants participating in this fun and enriching event, including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups.
Rose Pink Photography was at the 2017 APCaRI Fall Symposium and took these excellent images of the meeting, including the group photo seen in the featured image!

Plan on attending the 2018 Fall symposium to discuss and share ideas and enjoy the beautiful Rockies!
The APCaRI Fall symposium is generously supported by the Alberta Cancer Foundation and its’ donors.

- Perrin Beatty